Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ, Sardell RJ, Staplin N, Judge PK, Zhu D, Sammons E, Cherney DZI, Green JB, Levin A, Pontremoli R, Hauske SJ, Emberson J, Preiss D, Landray MJ, Baigent C, Wanner C, Haynes R, Herrington WG; EMPA-KIDNEY Collaborative Group. Mayne KJ, et al. Among authors: haynes r. Nephrol Dial Transplant. 2024 Sep 14:gfae203. doi: 10.1093/ndt/gfae203. Online ahead of print. Nephrol Dial Transplant. 2024. PMID: 39277784 Free PMC article.
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.
Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V, Pfeffer MA, Rossing P, Walsh M, Wanner C, Wheeler DC, Winkelmayer WC, McMurray JJV; KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants. Baigent C, et al. Kidney Int. 2017 Aug;92(2):297-305. doi: 10.1016/j.kint.2017.04.019. Kidney Int. 2017. PMID: 28709600 Free PMC article.
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Nuffield Department of Population Health Renal Studies Group, et al. Lancet. 2022 Nov 19;400(10365):1788-1801. doi: 10.1016/S0140-6736(22)02074-8. Epub 2022 Nov 6. Lancet. 2022. PMID: 36351458 Free PMC article.
Accelerating clinical trials: time to turn words into action.
Landray MJ, Haynes R, Reith C. Landray MJ, et al. Among authors: haynes r. Lancet. 2023 Jul 15;402(10397):165-168. doi: 10.1016/S0140-6736(23)01181-9. Epub 2023 Jun 9. Lancet. 2023. PMID: 37307840 No abstract available.
Delivering trials in the NHS: more than worth it.
Haynes R, Mafham M, Toh CH, Landray MJ. Haynes R, et al. Clin Med (Lond). 2023 Sep;23(5):525-526. doi: 10.7861/clinmed.2023-0296. Clin Med (Lond). 2023. PMID: 37775179 Free PMC article.
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
Wu R, Williams C, Zhou J, Schlackow I, Emberson J, Reith C, Keech A, Robson J, Armitage J, Gray A, Simes J, Baigent C, Mihaylova B; CTT Collaboration secretariat CTT Collaboration trialists: A to Z trial (phase Z) AFCAPS/TEXCAPS (AirForce/Texas Coronary Atherosclerosis Prevention Study)ALERT (Assessment of Lescol in Renal Transplantation)ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)ALLIANCE (Aggressive Lipid-Lowering Initiation Abates New Cardiac Events)ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial)ASPEN (Atorvastatin Study for the Prevention of Coronary Heart Disease Endpoints in Non-Insulin Dependent Diabetes Mellitus)AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events)CARDS (Collaborative Atorvastatin Diabetes Study)CARE (Cholesterol And Recurrent Events Study)CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure)4D (Die Deutsche Diabetes Dialyse Studie)GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico) Heart Failure and Prevention trialsHOPE-3HPS (Heart Protection Study)IDEAL (Incremental Decrease in E… See abstract for full author list ➔ Wu R, et al. Br J Gen Pract. 2024 Feb 29;74(740):e189-e198. doi: 10.3399/BJGP.2023.0198. Print 2024 Mar. Br J Gen Pract. 2024. PMID: 38373851 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 38614807
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.
Nangaku M, Herrington WG, Goto S, Maruyama S, Kashihara N, Ueki K, Wada J, Watada H, Nakashima E, Lee R, Massey D, Mayne KJ, Tomita A, Haynes R, Hauske SJ, Kadowaki T. Nangaku M, et al. Among authors: haynes r. Clin Exp Nephrol. 2024 Jun;28(6):588-595. doi: 10.1007/s10157-024-02489-4. Epub 2024 Apr 20. Clin Exp Nephrol. 2024. PMID: 38643286 Free PMC article. Clinical Trial.
1,228 results